Last reviewed · How we verify
Rituximab-pvvr
Rituximab-pvvr is a monoclonal antibody that targets the CD20 antigen on B-lymphocytes, leading to B-cell lysis through mechanisms such as complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).
Rituximab-pvvr (RUXIENCE) is a monoclonal antibody that targets the CD20 antigen on B-lymphocytes, leading to B-cell lysis. It is approved for treating Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), and Rheumatoid Arthritis (RA). Common side effects include infusion-related reactions, infections, and hematological issues. The drug has a boxed warning for severe infusion-related reactions, mucocutaneous reactions, hepatitis B reactivation, and progressive multifocal leukoencephalopathy.
At a glance
| Generic name | Rituximab-pvvr |
|---|---|
| Also known as | Ruxience |
| Sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Drug class | Monoclonal antibody |
| Target | CD20 antigen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Rituximab-pvvr binds to the CD20 antigen on the surface of pre-B and mature B-lymphocytes, which are involved in various autoimmune and inflammatory processes. This binding leads to the destruction of B-cells, reducing their role in conditions like rheumatoid arthritis and certain types of lymphoma.
Approved indications
Boxed warnings
- Fatal infusion-related reactions
- Severe mucocutaneous reactions
- Hepatitis B virus reactivation
- Progressive multifocal leukoencephalopathy
Common side effects
- infusion-related reactions
- fever
- lymphopenia
- chills
- infection
- asthenia
- neutropenia
- upper respiratory tract infection
- nasopharyngitis
- urinary tract infection
- bronchitis
Drug interactions
- Renal toxicity when used in combination with cisplatin
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia (PHASE1, PHASE2)
- Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial (PHASE2)
- Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (PHASE2)
- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (PHASE3)
- Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (PHASE1)
- Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (PHASE1)
- Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: